Works by Atsukawa, Masanori

Results: 161
    1

    Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues.

    Published in:
    Clinical & Molecular Hepatology, 2025, v. 31, n. 3, p. 1003, doi. 10.3350/cmh.2024.1070
    By:
    • Rui Huang;
    • Dae Won Jun;
    • Hidenori Toyoda;
    • Yao-Chun Hsu;
    • Trinh, Huy;
    • Akito Nozaki;
    • Toru Ishikawa;
    • Tsunamasa Watanabe;
    • Haruki Uojima;
    • Huang, Daniel Q.;
    • Takashi Honda;
    • Yasuhito Tanaka;
    • Vutien, Philip;
    • Marciano, Sebastián;
    • Hiroshi Abe;
    • Masaru Enomoto;
    • Masanori Atsukawa;
    • Hirokazu Takahashi;
    • Kunihiko Tsuji;
    • Koichi Takaguchi
    Publication type:
    Article
    2

    Clinical Impact of Serum CRP Levels on Advanced HCC Treated With Durvalumab and Tremelimumab: A Multicentre Study.

    Published in:
    Liver International, 2025, v. 45, n. 7, p. 1, doi. 10.1111/liv.70192
    By:
    • Hatanaka, Takeshi;
    • Yata, Yutaka;
    • Hiraoka, Atsushi;
    • Tada, Toshifumi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Kakizaki, Satoru;
    • Fukunishi, Shinya;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Toyoda, Hidenori;
    • Koshiyama, Yuichi;
    • Ogawa, Chikara;
    • Nishikawa, Hiroki;
    • Nishimura, Takashi
    Publication type:
    Article
    3

    Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve Function.

    Published in:
    Oncology, 2023, v. 101, n. 10, p. 624, doi. 10.1159/000531316
    By:
    • Hiraoka, Atsushi;
    • Kumada, Takashi;
    • Tada, Toshifumi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Ochi, Hironori;
    • Yasuda, Satoshi;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Nishimura, Takashi;
    • Hatanaka, Takeshi;
    • Kakizaki, Satoru
    Publication type:
    Article
    4

    Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical Settings.

    Published in:
    Oncology, 2023, v. 101, n. 9, p. 542, doi. 10.1159/000530028
    By:
    • Ohama, Hideko;
    • Hiraoka, Atsushi;
    • Tada, Toshifumi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Ochi, Hironori;
    • Yasuda, Satoshi;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Nishimura, Takashi;
    • Hatanaka, Takeshi;
    • Kakizaki, Satoru
    Publication type:
    Article
    5

    Nutritional Status Is Associated with Prognosis in Patients with Advanced Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab.

    Published in:
    Oncology, 2023, v. 101, n. 4, p. 270, doi. 10.1159/000527676
    By:
    • Tada, Toshifumi;
    • Kumada, Takashi;
    • Hiraoka, Atsushi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Hirooka, Masashi;
    • Takaguchi, Koichi;
    • Atsukawa, Masanori;
    • Fukunishi, Shinya;
    • Itobayashi, Ei;
    • Tsuji, Kunihiko;
    • Tajiri, Kazuto;
    • Ochi, Hironori;
    • Ishikawa, Toru;
    • Yasuda, Satoshi;
    • Ogawa, Chikara;
    • Toyoda, Hidenori;
    • Hatanaka, Takeshi;
    • Nishimura, Takashi;
    • Kakizaki, Satoru
    Publication type:
    Article
    6

    Clinical Predictor of Urinary Protein as Adverse Event Associated with Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma.

    Published in:
    Oncology, 2022, v. 100, n. 12, p. 645, doi. 10.1159/000526521
    By:
    • Hiraoka, Atsushi;
    • Kumada, Takashi;
    • Tada, Toshifumi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Ochi, Hironori;
    • Yasuda, Satoshi;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Nishimura, Takashi;
    • Hatanaka, Takeshi;
    • Kakizaki, Satoru
    Publication type:
    Article
    7

    Impact of Early Lenvatinib Administration on Survival in Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicenter, Inverse Probability Weighting Analysis.

    Published in:
    Oncology, 2021, v. 99, n. 8, p. 518, doi. 10.1159/000515896
    By:
    • Tada, Toshifumi;
    • Kumada, Takashi;
    • Hiraoka, Atsushi;
    • Michitaka, Kojiro;
    • Atsukawa, Masanori;
    • Hirooka, Masashi;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Takaguchi, Koichi;
    • Kariyama, Kazuya;
    • Itobayashi, Ei;
    • Tajiri, Kazuto;
    • Shimada, Noritomo;
    • Shibata, Hiroshi;
    • Ochi, Hironori;
    • Yasuda, Satoshi;
    • Toyoda, Hidenori;
    • Fukunishi, Shinya;
    • Ohama, Hideko;
    • Kawata, Kazuhito
    Publication type:
    Article
    8

    Nutritional Index as Prognostic Indicator in Patients Receiving Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma.

    Published in:
    Oncology, 2020, v. 98, n. 5, p. 295, doi. 10.1159/000506293
    By:
    • Hiraoka, Atsushi;
    • Kumada, Takashi;
    • Tada, Toshifumi;
    • Fukunishi, Shinya;
    • Atsukawa, Masanori;
    • Hirooka, Masashi;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Takaguchi, Koichi;
    • Kariyama, Kazuya;
    • Itobayashi, Ei;
    • Tajiri, Kazuto;
    • Shimada, Noritomo;
    • Shibata, Hiroshi;
    • Ochi, Hironori;
    • Kawata, Kazuhito;
    • Toyoda, Hidenori;
    • Ohama, Hideko;
    • Tsutsui, Akemi;
    • Itokawa, Norio
    Publication type:
    Article
    9

    Early Relative Change in Hepatic Function with Lenvatinib for Unresectable Hepatocellular Carcinoma.

    Published in:
    Oncology, 2019, v. 97, n. 6, p. 334, doi. 10.1159/000502095
    By:
    • Hiraoka, Atsushi;
    • Kumada, Takashi;
    • Atsukawa, Masanori;
    • Hirooka, Masashi;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Takaguchi, Koichi;
    • Kariyama, Kazuya;
    • Itobayashi, Ei;
    • Tajiri, Kazuto;
    • Shimada, Noritomo;
    • Shibata, Hiroshi;
    • Ochi, Hironori;
    • Tada, Toshifumi;
    • Toyoda, Hidenori;
    • Nouso, Kazuhiro;
    • Tsutsui, Akemi;
    • Nagano, Takuya;
    • Itokawa, Norio;
    • Hayama, Korenobu
    Publication type:
    Article
    10

    Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma.

    Published in:
    Oncology, 2019, v. 97, n. 5, p. 277, doi. 10.1159/000501281
    By:
    • Hiraoka, Atsushi;
    • Kumada, Takashi;
    • Atsukawa, Masanori;
    • Hirooka, Masashi;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Takaguchi, Koichi;
    • Kariyama, Kazuya;
    • Itobayashi, Ei;
    • Tajiri, Kazuto;
    • Shimada, Noritomo;
    • Shibata, Hiroshi;
    • Ochi, Hironori;
    • Tada, Toshifumi;
    • Toyoda, Hidenori;
    • Nouso, Kazuhiro;
    • Tsutsui, Akemi;
    • Nagano, Takuya;
    • Itokawa, Norio;
    • Hayama, Korenobu
    Publication type:
    Article
    11

    Characteristics of cabozantinib treatment in advanced hepatocellular carcinoma.

    Published in:
    Liver Cancer International, 2023, v. 4, n. 3, p. 101, doi. 10.1002/lci2.74
    By:
    • Nouso, Kazuhiro;
    • Shiota, Shohei;
    • Fujita, Rio;
    • Wakuta, Akiko;
    • Kariyama, Kazuya;
    • Hiraoka, Atsushi;
    • Atsukawa, Masanori;
    • Tani, Joji;
    • Tada, Toshifumi;
    • Matsuo, Yu;
    • Nakamura, Shinichiro;
    • Tajiri, Kazuto;
    • Kaibori, Masaki;
    • Hirooka, Masashi;
    • Itobayashi, Ei;
    • Kakizaki, Satoru;
    • Naganuma, Atsushi;
    • Ishikawa, Toru;
    • Hatanaka, Takeshi;
    • Fukunishi, Shinya
    Publication type:
    Article
    12

    Association Between Laboratory Values and Covert Hepatic Encephalopathy in Patients with Liver Cirrhosis: A Multicenter, Retrospective Study.

    Published in:
    Journal of Clinical Medicine, 2025, v. 14, n. 6, p. 1858, doi. 10.3390/jcm14061858
    By:
    • Koyano, Kaori;
    • Atsukawa, Masanori;
    • Tsubota, Akihito;
    • Kondo, Chisa;
    • Miwa, Takao;
    • Namisaki, Tadashi;
    • Hiraoka, Atsushi;
    • Toyoda, Hidenori;
    • Tada, Toshifumi;
    • Kobayashi, Yuji;
    • Kawata, Kazuhito;
    • Matsuura, Kentaro;
    • Mikami, Shigeru;
    • Kawabe, Naoto;
    • Oikawa, Tsunekazu;
    • Suzuki, Kenta;
    • Kawano, Tadamichi;
    • Okubo, Tomomi;
    • Arai, Taeang;
    • Tani, Joji
    Publication type:
    Article
    13

    Relationship of Atezolizumab plus Bevacizumab Treatment with Muscle Volume Loss in Unresectable Hepatocellular Carcinoma Patients: Multicenter Analysis.

    Published in:
    Liver Cancer (2235-1795), 2023, v. 12, n. 3, p. 209, doi. 10.1159/000527402
    By:
    • Hiraoka, Atsushi;
    • Kumada, Takashi;
    • Tada, Toshifumi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Ochi, Hironori;
    • Yasuda, Satoshi;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Nishimura, Takashi;
    • Hatanaka, Takeshi;
    • Kakizaki, Satoru
    Publication type:
    Article
    14

    Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study.

    Published in:
    Liver Cancer (2235-1795), 2022, v. 11, n. 6, p. 527, doi. 10.1159/000525145
    By:
    • Casadei-Gardini, Andrea;
    • Rimini, Margherita;
    • Kudo, Masatoshi;
    • Shimose, Shigeo;
    • Tada, Toshifumi;
    • Suda, Goki;
    • Goh, Myung Ji;
    • Jefremow, Andre;
    • Scartozzi, Mario;
    • Cabibbo, Giuseppe;
    • Campani, Claudia;
    • Tamburini, Emiliano;
    • Tovoli, Francesco;
    • Ueshima, Kazuomi;
    • Aoki, Tomoko;
    • Iwamoto, Hideki;
    • Torimura, Takuji;
    • Kumada, Takashi;
    • Hiraoka, Atsushi;
    • Atsukawa, Masanori
    Publication type:
    Article
    15

    Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma.

    Published in:
    Liver Cancer (2235-1795), 2021, v. 10, n. 5, p. 473, doi. 10.1159/000515552
    By:
    • Koroki, Keisuke;
    • Kanogawa, Naoya;
    • Maruta, Susumu;
    • Ogasawara, Sadahisa;
    • Iino, Yotaro;
    • Obu, Masamichi;
    • Okubo, Tomomi;
    • Itokawa, Norio;
    • Maeda, Takahiro;
    • Inoue, Masanori;
    • Haga, Yuki;
    • Seki, Atsuyoshi;
    • Okabe, Shinichiro;
    • Koma, Yoshihiro;
    • Azemoto, Ryosaku;
    • Atsukawa, Masanori;
    • Itobayashi, Ei;
    • Ito, Kenji;
    • Sugiura, Nobuyuki;
    • Mizumoto, Hideaki
    Publication type:
    Article
    16

    Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma.

    Published in:
    Liver Cancer (2235-1795), 2021, v. 10, n. 5, p. 473, doi. 10.1159/000515552
    By:
    • Koroki, Keisuke;
    • Kanogawa, Naoya;
    • Maruta, Susumu;
    • Ogasawara, Sadahisa;
    • Iino, Yotaro;
    • Obu, Masamichi;
    • Okubo, Tomomi;
    • Itokawa, Norio;
    • Maeda, Takahiro;
    • Inoue, Masanori;
    • Haga, Yuki;
    • Seki, Atsuyoshi;
    • Okabe, Shinichiro;
    • Koma, Yoshihiro;
    • Azemoto, Ryosaku;
    • Atsukawa, Masanori;
    • Itobayashi, Ei;
    • Ito, Kenji;
    • Sugiura, Nobuyuki;
    • Mizumoto, Hideaki
    Publication type:
    Article
    17

    What Can Be Done to Solve the Unmet Clinical Need of Hepatocellular Carcinoma Patients following Lenvatinib Failure?

    Published in:
    Liver Cancer (2235-1795), 2021, v. 10, n. 2, p. 115, doi. 10.1159/000513355
    By:
    • Atsushi Hiraoka;
    • Takashi Kumada;
    • Toshifumi Tada;
    • Kazuya Kariyama;
    • Joji Tani;
    • Shinya Fukunishi;
    • Masanori Atsukawa;
    • Masashi Hirooka;
    • Kunihiko Tsuji;
    • Toru Ishikawa;
    • Koichi Takaguchi;
    • Ei Itobayashi;
    • Kazuto Tajiri;
    • Noritomo Shimada;
    • Hiroshi Shibata;
    • Hironori Ochi;
    • Kazuhito Kawata;
    • Satoshi Yasuda;
    • Hidenori Toyoda;
    • Hideko Ohama
    Publication type:
    Article
    18

    Potential of Lenvatinib for an Expanded Indication from the REFLECT Trial in Patients with Advanced Hepatocellular Carcinoma.

    Published in:
    Liver Cancer (2235-1795), 2020, v. 9, n. 4, p. 382, doi. 10.1159/000507022
    By:
    • Maruta, Susumu;
    • Ogasawara, Sadahisa;
    • Ooka, Yoshihiko;
    • Obu, Masamichi;
    • Inoue, Masanori;
    • Itokawa, Norio;
    • Haga, Yuki;
    • Seki, Atsuyoshi;
    • Okabe, Shinichiro;
    • Azemoto, Ryosaku;
    • Itobayashi, Ei;
    • Atsukawa, Masanori;
    • Sugiura, Nobuyuki;
    • Mizumoto, Hideaki;
    • Koroki, Keisuke;
    • Kanayama, Kengo;
    • Kanzaki, Hiroaki;
    • Kobayashi, Kazufumi;
    • Kiyono, Soichiro;
    • Nakamura, Masato
    Publication type:
    Article
    19

    Post-Progression Treatment Eligibility of Unresectable Hepatocellular Carcinoma Patients Treated with Lenvatinib.

    Published in:
    Liver Cancer (2235-1795), 2020, v. 9, n. 1, p. 73, doi. 10.1159/000503031
    By:
    • Hiraoka, Atsushi;
    • Kumada, Takashi;
    • Fukunishi, Shinya;
    • Atsukawa, Masanori;
    • Hirooka, Masashi;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Takaguchi, Koichi;
    • Kariyama, Kazuya;
    • Itobayashi, Ei;
    • Tajiri, Kazuto;
    • Shimada, Noritomo;
    • Shibata, Hiroshi;
    • Ochi, Hironori;
    • Tada, Toshifumi;
    • Toyoda, Hidenori;
    • Yokohama, Keisuke;
    • Nouso, Kazuhiro;
    • Tsutsui, Akemi;
    • Nagano, Takuya
    Publication type:
    Article
    20

    Beneficial effect of oral semaglutide for type 2 diabetes mellitus in patients with metabolic dysfunction‐associated steatotic liver disease: A prospective, multicentre, observational study.

    Published in:
    Diabetes, Obesity & Metabolism, 2024, v. 26, n. 11, p. 4958, doi. 10.1111/dom.15898
    By:
    • Arai, Taeang;
    • Atsukawa, Masanori;
    • Tsubota, Akihito;
    • Oikawa, Tsunekazu;
    • Tada, Toshifumi;
    • Matsuura, Kentaro;
    • Ishikawa, Toru;
    • Abe, Hiroshi;
    • Kato, Keizo;
    • Morishita, Asahiro;
    • Tani, Joji;
    • Okubo, Tomomi;
    • Nagao, Mototsugu;
    • Iwabu, Masato;
    • Iwakiri, Katsuhiko
    Publication type:
    Article
    21

    Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: Comparative analysis of conversion, partial response and complete response patients.

    Published in:
    Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 10, p. 1361, doi. 10.1111/apt.18237
    By:
    • Hatanaka, Takeshi;
    • Kakizaki, Satoru;
    • Hiraoka, Atsushi;
    • Tada, Toshifumi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Nishikawa, Hiroki;
    • Nishimura, Takashi;
    • Kawata, Kazuhito;
    • Kosaka, Hisashi
    Publication type:
    Article
    22

    Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real‐world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial.

    Published in:
    Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 2, p. 233, doi. 10.1111/apt.18037
    By:
    • Tada, Toshifumi;
    • Kumada, Takashi;
    • Hiraoka, Atsushi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Nishikawa, Hiroki;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Koshiyama, Yuichi;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Hatanaka, Takeshi;
    • Kakizaki, Satoru;
    • Kawata, Kazuhito
    Publication type:
    Article
    23

    Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data.

    Published in:
    Therapeutic Advances in Endocrinology & Metabolism, 2021, p. 1, doi. 10.1177/20420188211000243
    By:
    • Arai, Taeang;
    • Atsukawa, Masanori;
    • Tsubota, Akihito;
    • Mikami, Shigeru;
    • Ono, Hiroki;
    • Kawano, Tadamichi;
    • Yoshida, Yuji;
    • Tanabe, Tomohide;
    • Okubo, Tomomi;
    • Hayama, Korenobu;
    • Nakagawa-Iwashita, Ai;
    • Itokawa, Norio;
    • Kondo, Chisa;
    • Kaneko, Keiko;
    • Emoto, Naoya;
    • Nagao, Mototsugu;
    • Inagaki, Kyoko;
    • Fukuda, Izumi;
    • Sugihara, Hitoshi;
    • Iwakiri, Katsuhiko
    Publication type:
    Article
    24

    Serum miR-192-5p levels predict the efficacy of pegylated interferon therapy for chronic hepatitis B.

    Published in:
    PLoS ONE, 2022, v. 17, n. 2, p. 1, doi. 10.1371/journal.pone.0263844
    By:
    • Nagura, Yoshihito;
    • Matsuura, Kentaro;
    • Iio, Etsuko;
    • Fujita, Koji;
    • Inoue, Takako;
    • Matsumoto, Akihiro;
    • Tanaka, Eiji;
    • Nishiguchi, Shuhei;
    • Kang, Jong-Hon;
    • Matsui, Takeshi;
    • Enomoto, Masaru;
    • Ikeda, Hiroki;
    • Watanabe, Tsunamasa;
    • Okuse, Chiaki;
    • Tsuge, Masataka;
    • Atsukawa, Masanori;
    • Tateyama, Masakuni;
    • Kataoka, Hiromi;
    • Tanaka, Yasuhito
    Publication type:
    Article
    25
    26
    27

    Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis.

    Published in:
    Cancer Medicine, 2019, v. 8, n. 8, p. 3719, doi. 10.1002/cam4.2241
    By:
    • Hiraoka, Atsushi;
    • Kumada, Takashi;
    • Atsukawa, Masanori;
    • Hirooka, Masashi;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Takaguchi, Koichi;
    • Kariyama, Kazuya;
    • Itobayashi, Ei;
    • Tajiri, Kazuto;
    • Shimada, Noritomo;
    • Shibata, Hiroshi;
    • Ochi, Hironori;
    • Tada, Toshifumi;
    • Toyoda, Hidenori;
    • Nouso, Kazuhiro;
    • Tsutsui, Akemi;
    • Nagano, Takuya;
    • Itokawa, Norio;
    • Hayama, Korenobu
    Publication type:
    Article
    28

    Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions: Multicenter analysis.

    Published in:
    Cancer Medicine, 2019, v. 8, n. 1, p. 137, doi. 10.1002/cam4.1909
    By:
    • Hiraoka, Atsushi;
    • Kumada, Takashi;
    • Kariyama, Kazuya;
    • Takaguchi, Koichi;
    • Atsukawa, Masanori;
    • Itobayashi, Ei;
    • Tsuji, Kunihiko;
    • Tajiri, Kazuto;
    • Hirooka, Masashi;
    • Shimada, Noritomo;
    • Shibata, Hiroshi;
    • Ishikawa, Toru;
    • Ochi, Hironori;
    • Tada, Toshifumi;
    • Toyoda, Hidenori;
    • Nouso, Kazuhiro;
    • Tsutsui, Akemi;
    • Itokawa, Norio;
    • Imai, Michitaka;
    • Joko, Kouji
    Publication type:
    Article
    29

    Geriatric nutritional risk index and newly developed scoring system as prognosis prediction for unresectable hepatocellular carcinoma patients treated with lenvatinib.

    Published in:
    Scientific Reports, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41598-024-78539-4
    By:
    • Ohama, Hideko;
    • Hiraoka, Atsushi;
    • Tada, Toshifumi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Ochi, Hironori;
    • Yasuda, Satoshi;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Nishimura, Takashi;
    • Hatanaka, Takeshi;
    • Kakizaki, Satoru
    Publication type:
    Article
    30

    The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study.

    Published in:
    Alimentary Pharmacology & Therapeutics, 2019, v. 49, n. 9, p. 1230, doi. 10.1111/apt.15218
    By:
    • Atsukawa, Masanori;
    • Tsubota, Akihito;
    • Toyoda, Hidenori;
    • Takaguchi, Koichi;
    • Nakamuta, Makoto;
    • Watanabe, Tsunamasa;
    • Michitaka, Kojiro;
    • Ikegami, Tadashi;
    • Nozaki, Akito;
    • Uojima, Haruki;
    • Fukunishi, Shinya;
    • Genda, Takuya;
    • Abe, Hiroshi;
    • Hotta, Naoki;
    • Tsuji, Kunihiko;
    • Ogawa, Chikara;
    • Tachi, Yoshihiko;
    • Shima, Toshihide;
    • Shimada, Noritomo;
    • Kondo, Chisa
    Publication type:
    Article
    31

    Factors influencing subclinical atherosclerosis in patients with biopsy-proven nonalcoholic fatty liver disease.

    Published in:
    PLoS ONE, 2019, v. 14, n. 11, p. 1, doi. 10.1371/journal.pone.0224184
    By:
    • Arai, Taeang;
    • Atsukawa, Masanori;
    • Tsubota, Akihito;
    • Kawano, Tadamichi;
    • Koeda, Mai;
    • Yoshida, Yuji;
    • Tanabe, Tomohide;
    • Okubo, Tomomi;
    • Hayama, Korenobu;
    • Iwashita, Ai;
    • Itokawa, Norio;
    • Kondo, Chisa;
    • Kaneko, Keiko;
    • Kawamoto, Chiaki;
    • Hatori, Tsutomu;
    • Emoto, Naoya;
    • Iio, Etsuko;
    • Tanaka, Yasuhito;
    • Iwakiri, Katsuhiko
    Publication type:
    Article
    32

    Identification of CT Values That Could Be Predictive of Necrosis (N-CTav) in Hepatocellular Carcinoma after Lenvatinib Treatment.

    Published in:
    Current Oncology, 2022, v. 29, n. 5, p. 3259, doi. 10.3390/curroncol29050266
    By:
    • Chuma, Makoto;
    • Yokoo, Hideki;
    • Hiraoka, Atsushi;
    • Ueda, Kazuhiko;
    • Yokoyama, Takahiro;
    • Tsuji, Kunihiko;
    • Shimada, Noritomo;
    • Uojima, Haruki;
    • Kobayashi, Satoshi;
    • Hattori, Nobuhiro;
    • Okubo, Tomomi;
    • Atsukawa, Masanori;
    • Ishikawa, Toru;
    • Takaguchi, Koichi;
    • Tsutsui, Akemi;
    • Toyoda, Hidenori;
    • Tada, Toshifumi;
    • Saito, Yoshinori;
    • Hirose, Shunji;
    • Tanaka, Takaaki
    Publication type:
    Article
    33

    Switching from entecavir to tenofovir disoproxil fumarate for HBeAg-positive chronic hepatitis B patients: a phase 4, prospective study.

    Published in:
    2021
    By:
    • Suzuki, Fumitaka;
    • Suzuki, Yoshiyuki;
    • Karino, Yoshiyasu;
    • Tanaka, Yasuhito;
    • Kurosaki, Masayuki;
    • Yatsuhashi, Hiroshi;
    • Atarashi, Tomofumi;
    • Atsukawa, Masanori;
    • Watanabe, Tsunamasa;
    • Enomoto, Masaru;
    • Kudo, Masatoshi;
    • Maeda, Naoto;
    • Kohno, Hiroshi;
    • Joko, Kouji;
    • Michitaka, Kojiro;
    • Miki, Koichiro;
    • Takahashi, Kazuhiro;
    • Ide, Tatsuya;
    • Fujiyama, Shigetoshi;
    • Kohno, Tomoko
    Publication type:
    journal article
    34

    Prediction of cccDNA dynamics in hepatitis B patients by a combination of serum surrogate markers.

    Published in:
    PLoS Computational Biology, 2025, v. 21, n. 1, p. 1, doi. 10.1371/journal.pcbi.1012615
    By:
    • Kim, Kwang Su;
    • Iwamoto, Masashi;
    • Kitagawa, Kosaku;
    • Park, Hyeongki;
    • Hayashi, Sanae;
    • Tsukuda, Senko;
    • Matsui, Takeshi;
    • Atsukawa, Masanori;
    • Matsuura, Kentaro;
    • Chuaypen, Natthaya;
    • Tangkijvanich, Pisit;
    • Allweiss, Lena;
    • Nishiyama, Takara;
    • Nakamura, Naotoshi;
    • Fujita, Yasuhisa;
    • Kawakami, Eiryo;
    • Nakaoka, Shinji;
    • Muramatsu, Masamichi;
    • Aihara, Kazuyuki;
    • Wakita, Takaji
    Publication type:
    Article
    35
    36

    Multicenter Study of Pegylated Interferon α-2a Monotherapy for Hepatitis C Virus-Infected Patients on Hemodialysis: REACH Study.

    Published in:
    Therapeutic Apheresis & Dialysis, 2014, v. 18, n. 6, p. 603, doi. 10.1111/1744-9987.12189
    By:
    • Kikuchi, Kan;
    • Akiba, Takashi;
    • Nitta, Kosaku;
    • Masakane, Ikuto;
    • Ando, Ryoichi;
    • Izumi, Namiki;
    • Atsukawa, Masanori;
    • Yamazaki, Chikao;
    • Kato, Fumi;
    • Hotta, Naoki;
    • Tominaga, Yoshihiro;
    • Orito, Etsuro;
    • Hora, Kazuhiko;
    • Nagasawa, Masaki;
    • Kasahara, Hiroshi;
    • Kawaguchi, Masanori;
    • Kimura, Hiroyuki;
    • Ikebe, Norisato;
    • Kawanishi, Hideki;
    • Moriishi, Misaki
    Publication type:
    Article
    37

    Impact of pemafibrate in patients with metabolic dysfunction‐associated steatotic liver disease complicated by dyslipidemia: A single‐arm prospective study.

    Published in:
    JGH Open, 2024, v. 8, n. 4, p. 1, doi. 10.1002/jgh3.13057
    By:
    • Ono, Hiroki;
    • Atsukawa, Masanori;
    • Tsubota, Akihito;
    • Arai, Taeang;
    • Suzuki, Kenta;
    • Higashi, Tetsuyuki;
    • Kitamura, Michika;
    • Shioda‐Koyano, Kaori;
    • Kawano, Tadamichi;
    • Yoshida, Yuji;
    • Okubo, Tomomi;
    • Hayama, Korenobu;
    • Itokawa, Norio;
    • Kondo, Chisa;
    • Nagao, Mototsugu;
    • Iwabu, Masato;
    • Iwakiri, Katsuhiko
    Publication type:
    Article
    38

    How do the 2022 European Society of Cardiology/European Respiratory Society guidelines modify the diagnosis of portopulmonary hypertension in patients with cirrhosis complicated by portal hypertension? A post hoc analysis.

    Published in:
    JGH Open, 2023, v. 7, n. 8, p. 588, doi. 10.1002/jgh3.12949
    By:
    • Atsukawa, Masanori;
    • Tsubota, Akihito;
    • Tamura, Yuichi;
    • Koyano‐Shioda, Kaori;
    • Kawano, Tadamichi;
    • Okubo, Tomomi;
    • Hayama, Korenobu;
    • Arai, Taeang;
    • Itokawa, Norio;
    • Taniguchi, Yu;
    • Tamura, Yudai;
    • Kondo, Chisa;
    • Iwakiri, Katsuhiko
    Publication type:
    Article
    39
    40
    41

    Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B.

    Published in:
    JGH Open, 2021, v. 5, n. 1, p. 34, doi. 10.1002/jgh3.12443
    By:
    • Itokawa, Norio;
    • Atsukawa, Masanori;
    • Tsubota, Akihito;
    • Takaguchi, Koichi;
    • Nakamuta, Makoto;
    • Hiraoka, Atsushi;
    • Kato, Keizo;
    • Abe, Hiroshi;
    • Mikami, Shigeru;
    • Shimada, Noritomo;
    • Chuma, Makoto;
    • Akito, Nozaki;
    • Uojima, Haruki;
    • Ogawa, Chikara;
    • Asano, Toru;
    • Tani, Joji;
    • Morishita, Asahiro;
    • Senoh, Tomonori;
    • Yamashita, Naoki;
    • Oikawa, Tsunekazu
    Publication type:
    Article
    42
    43

    Galectin-9 in Gastroenterological Cancer.

    Published in:
    International Journal of Molecular Sciences, 2023, v. 24, n. 7, p. 6174, doi. 10.3390/ijms24076174
    By:
    • Morishita, Asahiro;
    • Oura, Kyoko;
    • Tadokoro, Tomoko;
    • Shi, Tingting;
    • Fujita, Koji;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Masaki, Tsutomu
    Publication type:
    Article
    44
    45

    Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma.

    Published in:
    Gastroenterology Report, 2021, v. 9, n. 2, p. 133, doi. 10.1093/gastro/goaa042
    By:
    • Hiraoka, Atsushi;
    • Kumada, Takashi;
    • Tada, Toshifumi;
    • Ogawa, Chikara;
    • Tani, Joji;
    • Fukunishi, Shinya;
    • Atsukawa, Masanori;
    • Hirooka, Masashi;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Takaguchi, Koichi;
    • Kariyama, Kazuya;
    • Itobayashi, Ei;
    • Tajiri, Kazuto;
    • Shimada, Noritomo;
    • Shibata, Hiroshi;
    • Ochi, Hironori;
    • Kawata, Kazuhito;
    • Toyoda, Hidenori;
    • Ohama, Hideko
    Publication type:
    Article
    46

    Survival Outcomes Associated With Radiological Progressive Disease Subtypes in Patients With Atezolizumab and Bevacizumab–Treated HCC.

    Published in:
    Journal of Gastroenterology & Hepatology, 2025, v. 40, n. 4, p. 949, doi. 10.1111/jgh.16884
    By:
    • Matono, Tomomitsu;
    • Tada, Toshifumi;
    • Kumada, Takashi;
    • Hiraoka, Atsushi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Nishikawa, Hiroki;
    • Tanaka, Kazunari;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Koshiyama, Yuichi;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Hatanaka, Takeshi
    Publication type:
    Article
    47

    Reliable Performance of mALBI Grade‐Based Risk Models for Predicting the Prognosis of Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab as First‐Line Treatment: Comparative Analysis of 13 Risk Models.

    Published in:
    Journal of Gastroenterology & Hepatology, 2025, v. 40, n. 4, p. 930, doi. 10.1111/jgh.16871
    By:
    • Hatanaka, Takeshi;
    • Kakizaki, Satoru;
    • Hiraoka, Atsushi;
    • Tada, Toshifumi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Nishikawa, Hiroki;
    • Nishimura, Takashi;
    • Kawata, Kazuhito;
    • Kosaka, Hisashi
    Publication type:
    Article
    48

    Mortality in patients with chronic hepatitis B treated with tenofovir or entecavir: A multinational study.

    Published in:
    Journal of Gastroenterology & Hepatology, 2024, v. 39, n. 6, p. 1190, doi. 10.1111/jgh.16537
    By:
    • Jang, Tyng‐Yuan;
    • Liang, Po‐Cheng;
    • Jun, Dae Won;
    • Jung, Jang Han;
    • Toyoda, Hidenori;
    • Wang, Chih‐Wen;
    • Yuen, Man‐Fung;
    • Cheung, Ka Shing;
    • Yasuda, Satoshi;
    • Kim, Sung Eun;
    • Yoon, Eileen L;
    • An, Jihyun;
    • Enomoto, Masaru;
    • Kozuka, Ritsuzo;
    • Chuma, Makoto;
    • Nozaki, Akito;
    • Ishikawa, Toru;
    • Watanabe, Tsunamasa;
    • Atsukawa, Masanori;
    • Arai, Taeang
    Publication type:
    Article
    49

    Comparison of six hepatocellular carcinoma prediction models in Japanese patients after sustained virologic response undergoing rigorous surveillance for hepatocellular carcinoma.

    Published in:
    Journal of Gastroenterology & Hepatology, 2024, v. 39, n. 5, p. 949, doi. 10.1111/jgh.16494
    By:
    • Toyoda, Hidenori;
    • Tada, Toshifumi;
    • Uojima, Haruki;
    • Nozaki, Akito;
    • Chuma, Makoto;
    • Takaguchi, Koichi;
    • Hiraoka, Atsushi;
    • Abe, Hiroshi;
    • Itobayashi, Ei;
    • Matsuura, Kentaro;
    • Atsukawa, Masanori;
    • Watanabe, Tsunamasa;
    • Shimada, Noritomo;
    • Nakamuta, Makoto;
    • Kojima, Motoyuki;
    • Tsuji, Kunihiko;
    • Mikami, Shigeru;
    • Ishikawa, Toru;
    • Yasuda, Satoshi;
    • Tsutsui, Akemi
    Publication type:
    Article
    50

    Impact of first‐line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.

    Published in:
    Journal of Gastroenterology & Hepatology, 2023, v. 38, n. 8, p. 1389, doi. 10.1111/jgh.16225
    By:
    • Tada, Toshifumi;
    • Kumada, Takashi;
    • Hiraoka, Atsushi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Ochi, Hironori;
    • Yasuda, Satoshi;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Nishimura, Takashi;
    • Hatanaka, Takeshi;
    • Kakizaki, Satoru
    Publication type:
    Article